Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Trial of Oral PX-866 (a PI-3K Inhibitor) in Patients with Advanced Solid Tumors.

Trial Profile

A Phase I Trial of Oral PX-866 (a PI-3K Inhibitor) in Patients with Advanced Solid Tumors.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sonolisib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Cascadian Therapeutics; ProlX Pharmaceuticals
  • Most Recent Events

    • 12 May 2011 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
    • 18 Nov 2010 Interim results have been presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2010)
    • 07 Jun 2010 Enrollment is complete for the intermittent dosing group in this trial. Patients are still being recruited for the continuous dosing arm, according to an Oncothyreon media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top